← Eichor
Condition: Mucosal Melanoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Mucosal Melanoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
Phase 1/Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06961357Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
Phase 2 · 1 location(s) · Melanoma Institute Australia · NCT06999980Neo-adjuvant Immunotherapy in Patients With Localized Melanoma
Phase 2 · 6 location(s) · UNICANCER · NCT07230613Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
Phase 2 · 1 location(s) · University Health Network, Toronto · NCT06319196Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Phase 3 · 82 location(s) · Immunocore Ltd · NCT05549297Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07336979Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
Phase 2 · 1 location(s) · Washington University School of Medicine · NCT04318717A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Mela
Phase 1 · 4 location(s) · Alpha-9 Oncology USA Inc. · NCT07076550Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study
Phase N/A · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT07215988Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
Phase 2 · 2 location(s) · Memorial Sloan Kettering Cancer Center · NCT05384496A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05546827Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery
Phase 2 · 1 location(s) · The First Hospital of Jilin University · NCT07400302A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Select
Phase 1 · 2 location(s) · Kupando GmbH · NCT07600476The Registry Study of Genetic Alterations of Melanoma in Taiwan
Phase N/A · 16 location(s) · National Health Research Institutes, Taiwan · NCT06952400Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
Phase 2 · 2 location(s) · Emory University · NCT07155317A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectabl
Phase 2 · 31 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06797297A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V60
Phase 2 · 331 location(s) · SWOG Cancer Research Network · NCT04511013
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.